Skip to main content
SpringerLink
Log in

Risk-Adjusted Performance Measures: A Comment on Elbasha

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 17 June 2022

A Letter to the Editor to this article was published on 17 June 2022

The Original Article was published on 09 February 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Elbasha E. Cost-effectiveness risk-aversion curves: comparison of risk-adjusted performance measures and expected-utility approaches. Pharmacoeconomics. 2022;40:497–507. https://doi.org/10.1007/s40273-021-01123-5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sendi P. Dealing with bad risk in cost-effectiveness analysis: the cost-effectiveness risk-aversion curve. Pharmacoeconomics. 2021;39:161–9.

    Article  Google Scholar 

  3. Sendi P, Matter-Walstra K, Schwenkglenks M. Handling uncertainty in cost-effectiveness analysis: budget impact and risk aversion. Healthcare. 2021;9:1419. https://doi.org/10.1007/s40273-020-00969-5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Plantinga A, van der Meer R, Sortino F. The impact of downside risk on risk-adjusted performace of mutual funds in the Euronext markets. (July 19, 2001), Available at https://doi.org/10.2139/ssrn.277352.

  5. Jia J, Dyer JS. A standard measure of risk and risk-value models. Manage Sci. 1996;42(12):1691–705.

    Article  Google Scholar 

  6. Sortino F, van der Meer R, Plantinga A. The dutch triangle: a framework to measure upside potential relative to downside risk. J Portf Manag. 1999;26(1):50–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Clinical Epidemiology, Basel University Hospital, Spitalstrasse 12, 4031, Basel, Switzerland

    Pedram Sendi

  2. Institute of Pharmaceutical Medicine (ECPM), University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland

    Matthias Schwenkglenks

Authors
  1. Pedram Sendi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Schwenkglenks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pedram Sendi.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest; this commentary received no funding.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sendi, P., Schwenkglenks, M. Risk-Adjusted Performance Measures: A Comment on Elbasha. PharmacoEconomics 40, 739–740 (2022). https://doi.org/10.1007/s40273-022-01153-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-022-01153-7

Search

Navigation